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lot of ground has been covered since the demonstration of
lopidogrel response variability that initially questioned the
ationale of a “one-size-fits-all” antiplatelet strategy to treat
ercutaneous coronary intervention (PCI)/acute coronary
yndrome patients (1). Experiments modulating cytochrome
450 enzyme activity demonstrated the important relation
f the latter to the pharmacodynamic effect of clopidogrel
2). Likewise, single nucleotide polymorphisms of a cyto-
hrome P450 (CYP) gene encoding a key enzyme in the
etabolic activation of clopidogrel have been associated
ith pharmacokinetic and pharmacodynamic responses to
lopidogrel (3,4). High clopidogrel loading doses or repet-
See page 1001
tive loads have been effective in enhancing the pharmaco-
ynamic response (5,6). Recently, the aforementioned find-
ngs have gained interest after their clinical relevance was
xposed by the explosion of data demonstrating the link
etween ex vivo measurements of platelet reactivity to
denosine diphosphate (ADP) and post-PCI ischemic event
ccurrence (7). Intriguingly, it seems that risk grows signif-
cantly after a threshold of platelet reactivity (high on-
reatment platelet reactivity [HPR] to ADP) is exceeded.
ndeed, HPR is now achieving status as a major risk factor
or the PCI patient (8). The threshold idea has big impli-
ations for personalized antiplatelet therapy and is used in
he study by Barker et al. (9) in this issue of JACC:
ardiovascular Interventions; the VerifyNow assay is em-
loyed to measure platelet reactivity, and the cut point is
ased on a previous investigation (10). The therapeutic goal
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
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schemic risk but, to avoid bleeding, not drive it too low (7).
Importantly, the antiplatelet effect of clopidogrel is be-
olden to multiple influences. The primary explanation for
esponse variability and HPR is variable and limited clopi-
ogrel active metabolite generation by hepatic CYP en-
ymes, respectively. Active metabolite formation is influ-
nced by interactions with proton pump inhibitors, statins,
alcium channel blockers, smoking, St. John’s wort, and
-warfarin and single nucleotide polymorphisms of the
enes encoding the CYP isoenzymes. In addition, diabetes,
ody mass index, and disease acuity influence platelet
eactivity (11). The unpredictable antiplatelet effect of
lopidogrel and the HPR-ischemic risk link have provided a
olid foundation for 2 important developments: 1) new
2Y12 receptor blockers that have more rapid, potent, and
redictable pharmacodynamic effects; and 2) personalized
ntiplatelet therapy based on ex vivo assays.
Recently, the Food and Drug Administration issued a
boxed warning” highlighting the relation of the CYP2C19
athway to clopidogrel active metabolite generation. The
elation between poor clopidogrel metabolizers defined by
enetic testing (loss-of-function [LOF] homozygotes) and
ncreased risk was highlighted (12). The warning implied
hat poor metabolizers should be identified and treated with
alternative treatment or treatment strategies.” Thus, the
ork of Barker et al. is timely. Although it is believed that
he LOF allele confers its clinical risk by affecting the
harmacodynamic response to clopidogrel, no study has
emonstrated a conclusive link between the presence of an
OF allele, suboptimal clopidogrel active metabolite gen-
ration (pharmacokinetic measurement), decreased clopi-
ogrel responsiveness (pharmacodynamic measurement),
nd adverse clinical outcomes (Fig. 1). In line with the Food
nd Drug Administration warning, some have urged imme-
iate and widespread implementation of genotyping alone
o personalize antiplatelet therapy, whereas others have
rged a more cautious approach, because the safety and
fficacy of altering therapy in response to genetic testing is
ntirely unknown as recognized in an American College of
ardiology Foundation/American Heart Association Clin-
cal Alert (11,13,14).
The work of Barker et al. (9) is relevant to 2 major
uestions of the interventional cardiologist: 1) When should
latelet function testing and/or genotyping be performed?
) How well does 150 mg/day clopidogrel overcome HPR?
hey treated 41 coronary artery disease patients with HPR
n 75 mg/day clopidogrel with 150 mg/day for 7 days. It is
nclear how patients were recruited and how many were
creened. Patients were genotyped for CYP2C19 LOF and
ain-of-function alleles. “One-half” describes the pharma-
odynamic and genetic messages of this study: 1) one-half
ad at least 1 LOF allele; 2) one-half had HPR overcome by
igh-dose clopidogrel; and 3) one-half carrying an LOF
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1009llele had HPR overcome by high-dose clopidogrel. These
ata are consistent with previous observations where the
ensitivity of *2 carrier status in predicting HPR was
pproximately 50% (15,16). Interestingly, in the current
tudy 15% were ultra-rapid metabolizers and, on the basis of
enotyping, would not be expected to have HPR. Although
he authors conclude that LOF carriage does not have a
ajor influence on dose effect, the number of patients
tudied makes their conclusion tenuous.
On the basis of the current study, LOF carrier state is
either a robust surrogate for HPR nor a marker to predict
he pharmacodynamic response to double-dose clopidogrel
aintenance therapy in patients with HPR (9). If one chose
o personalize antiplatelet therapy on the basis of genotype,
any patients with HPR would be missed. Except for
erhaps *2 homozygotes, genotype cannot predict response
o high-dose clopidogrel. On the basis of Barker’s data, the
nswer to question number 1 would be that genotyping plays a
imited role diagnostically in choosing therapy for patients
lready receiving clopidogrel. Its role in clopidogrel-naive
atients remains unexplored.
Regarding question number 2: in addition to strategies
nvolving high-dose clopidogrel, new P2Y12 inhibitors (pra-
ugrel, ticagrelor, and elinogrel) overcome HPR. High-
oading-dose clopidogrel is a better strategy to inhibit
latelets than standard dose (5). However, in a recent study
f coronary artery disease patients, approximately 35%
Pharmacogenetic Measurement (CYP2C19*2)
Pharmacokinetic Measurement 
2
(reduced clopidogrel active metabolite 
generation)
3
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Pharmacodynamic Measurement
(high on-treatment platelet reactivity)
4
5
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Figure 1. Relation of Pharmacogenetic, Pharmacokinetic, and
Pharmacodynamic Measurements and Clinical Outcomes in Patients
Treated With Clopidogrel
Studies have independently correlated: 1) pharmacogenetic measurements
(PG) to pharmacodynamic measurements (PD); 2) PG to pharmacokinetic
measurements (PK); 3) PK to PD; 4) PG to clinical outcomes; and 5) PD to
clinical outcomes. A deﬁnitive link between PG, PK, and PD and clinical
outcomes has never been examined in a single large-scale prospective
study. The ‘?’ addresses whether there could be other effects of loss-of-
function allele on outcomes independent of effects of clopidogrel metabo-
lism. ACS  acute coronary syndrome; PCI  percutaneous coronary
intervention.xhibited HPR on the basis of the VerifyNow thresholdespite a high loading dose (17). These data and the current
tudy data indicate that high loading or maintenance doses
ight not be an effective strategy to overcome HPR in
any patients. However, another study reported that re-
eated 600-mg loading (up to 2,400 mg) can overcome
PR in 86% of patients and lower 1-month post-PCI
schemic risk (6). In addition, treating HPR patients un-
ergoing PCI with a glycoprotein IIb/IIIa inhibitor has
een associated with lower periprocedural ischemic risk
18). Also, the addition of cilostazol enhanced platelet
nhibition (19). Finally, the direct-acting P2Y12 inhibitors
icagrelor and elinogrel seem very effective in overcoming
PR, irrespective of genotype (approximately 100% of
atients with HPR receiving standard clopidogrel therapy
re below the threshold after switching to ticagrelor)
17,20). Thus, in the era of the new P2Y12 inhibitors,
enotyping to predict response to clopidogrel might become
ess relevant.
On the basis of the pilot work of Barker et al. (9) and
thers (21), it does not seem that genotype correlates well
nough with phenotype to adequately predict clopidogrel
esponsiveness in the HPR patient; nor does it seem
hat high-maintenance-dose clopidogrel is the optimal
emedy for HPR. However, the clinical efficacy of high-
aintenance-dose clopidogrel in the HPR patient will be
xamined prospectively in the GRAVITAS (Gauging Re-
ponsiveness with A VerifyNow assay–Impact on Throm-
osis and Safety) trial. The entire interventional community
nxiously awaits the results of this important trial that will
rovide the best answer thus far to the second question.
eprint requests and correspondence: Dr. Paul A. Gurbel, Sinai
enter for Thrombosis Research, Cardiac Catheterization Laborato-
ies, Sinai Hospital of Baltimore, 2401 West Belvedere Avenue,
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